S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome
Nancy A. Kernan,Stephan A. Grupp,Angela R. Smith,Sally Arai,Brandon M. Triplett,Joseph H. Antin,Leslie Lehmann,Tsiporah B. Shore,Vincent T. Ho,Nancy Bunin,Massimo Iacobelli,Wei Liang,Robin Hume,William Tappe,Robert J. Soiffer,Paul G. Richardson +15 more
TL;DR: In the completed T‐IND, the Kaplan–Meier estimated Day +100 survival for 1000 patients with documented defibrotide treatment after HSCT was 58·9% [95% confidence interval (CI), 55·7–61·9%; post hoc analyses were performed], and all patient subgroups without MOD had higher Day + 100 survival than those with MOD.
Journal ArticleDOI
Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study
TL;DR: It is suggested that children with ES should be screened for ALPS with DNTs, and Severity of cytopenias and elevated immunoglobulin levels also predicted ALPS.
Journal Article
The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease.
Suzanne Shusterman,Stephan A. Grupp,Rosalind Barr,David Carpentieri,Huaqing Zhao,John M. Maris +5 more
TL;DR: Data show that TNP-470 is a potent inhibitor of human neuroblastoma growth rate and tumorigenicity, and it is speculated that T NP-470 may be a useful adjuvant therapy for high-risk Neuroblastoma patients, particularly when used in settings of minimal disease status.
Journal ArticleDOI
Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia
Stephan A. Grupp,Stephan A. Grupp,Shannon L. Maude,Shannon L. Maude,Susana Rives,André Baruchel,Michael Boyer,Henrique Bittencourt,Peter Bader,Jochen Büchner,Theodore W. Laetsch,Heather E. Stefanski,G.D. Myers,Muna Qayed,Michael A. Pulsipher,Barbara De Moerloose,Gregory A. Yanik,Kara L. Davis,Paul L. Martin,Eneida R. Nemecek,Christina Peters,Joerg Krueger,Adriana Balduzzi,N Boissel,Francoise Mechinaud,Mimi Leung,Lamis K. Eldjerou,Lan Yi,Karen Thudium Mueller,Eric Bleickardt,Hidefumi Hiramatsu +30 more
TL;DR: The primary objective was met, with an overall remission rate (ORR) of 81% (complete remission [CR] + CR with incomplete blood count recovery [CRi], and the primary endpoint, ORR within 3 mo and maintained for ≥28 d among infused pts, was assessed by an independent review committee.
Journal ArticleDOI
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.
Ankit Kansagra,Noelle V. Frey,Merav Bar,Theodore W. Laetsch,Paul A. Carpenter,Bipin N. Savani,Helen E. Heslop,Catherine M. Bollard,Krishna V. Komanduri,Dennis A. Gastineau,Christian Chabannon,Miguel Perales,Michael Hudecek,Mahmoud Aljurf,Leslie A. Andritsos,John A. Barrett,Veronika Bachanova,Chiara Bonini,Armin Ghobadi,Saar Gill,Joshua A. Hill,Saad S. Kenderian,Partow Kebriaei,Arnon Nagler,David G. Maloney,Hien D. Liu,Nirali N. Shah,Mohamed A. Kharfan-Dabaja,Elizabeth J. Shpall,Ghulam J. Mufti,Laura Johnston,Elad Jacoby,Ali Bazarbachi,John F. DiPersio,Steven Z. Pavletic,David L. Porter,Stephan A. Grupp,Michel Sadelain,Mark R. Litzow,Mohamad Mohty,Shahrukh K. Hashmi +40 more
TL;DR: An initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved is presented.